Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dyslipidemia for each country…

Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dyslipidemia for each country…

Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dyslipidemia for each country…

Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the total and diagnosed prevalence of…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key dyslipidemia patient populations, covering 171 countries and more…

Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dyslipidemia for each country…

Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dyslipidemia for each country…

Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dyslipidemia for each country…

Dyslipidemia, characterized by abnormal lipid levels, plays a pivotal role in the development of cardiovascular (CV) disease. Physicians address this risk with various lipid-modifying therapies…

Dyslipidemia, characterized by abnormal lipid levels, plays a pivotal role in the development of cardiovascular (CV) disease. To address this risk factor, physicians use a range of lipid-modifying…

Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates,omega-3 fatty acid compounds, and PCSK9…

Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and PCSK9…